Calpains: Physiological and pathophysiological significance

Pathophysiology

Volumn 6, Issue 2, 1999, Pages 91-102

  Sazontova, Tatiana G ^a   Matskevich, Alexey A ^a   Arkhipenko, Yuriy V ^a  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

Author keywords

Apoptosis; Calpain; Calpastatin; Free radicals; Pathology; Proteolysis

Indexed keywords

CALPAIN;

APOPTOSIS; CELL DESTRUCTION; CONFORMATIONAL TRANSITION; CYTOSKELETON; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0032867856     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4680(99)00015-2     Document Type: Review

References (141)

1. Ouali A., Demeyer D., Raichon C. An introduction to the workshop. Biochimie. 74:1992;213-215.
2. Koohmaraie M. Ovine skeletal muscle multicatalytic proteinase complex (proteasome) purification, characterization, and comparison of its effects on myofibrils with mu-calpains. J. Animal Sci. 70:1992;3697-3708.
3. Melloni E., Salamino F., Sparatore B. The calpain-calpastatin system in mammalian cells properties and possible functions. Biochimie. 74:1992;217-223.
4. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
5. Jason J., Kang K., Michael D., Srinivasa M., Emad S., David J., Bjornsti M. Cascades of mammalian caspase activation in the yeast saccharomyces cerevisiae. J. Biol. Chem. 274:1999;3189-3198.
6. Leist M., Volbracht C., Kuhnle S., Fava E., Ferrando-May E., Nicotera P. Caspase-mediated apoptosis in neuronal excitotoxicity triggered by nitric oxide. Mol. Med. 3:1997;750-764.
7. Solary E., Eymin B., Droin N., Haugg M. Proteases, proteolysis, and apoptosis. Cell. Biol. Toxicol. 14:1998;121-132.
8. Waterhouse N., Finucane D., Green D., Elce J., Kumar S., Alnemri E., Litwack G., Khanna K., Lavin M., Watters D. Calpain activation is upstream of caspases in radiation-induced apoptosis. Cell Death Differ. 5:1998;1051-1061.
9. Porn-Ares M., Samali A., Orrenius S. Cleavage of the calpain inhibitor, calpastatin, during apoptosis. Cell Death Differ. 5:1998;1028-1033.
10. Dourdin N., Balcerzak D., Brustis J., Poussard S., Cottin P., Ducastaing A. Potential m-calpain substrates during myoblast fusion. Exp. Cell. Res. 246:1999;433-442.
11. Kohli V., Madden J., Bentley R., Clavien P. Calpain mediates ischemic injury of the liver through modulation of apoptosis and necrosis. Gastroenterology. 116:1999;168-178.
12. Sorimachi H., Kimura S., Kinbara K., Kazama J., Takahashi M., Yajima H., Ishiura S., Sasagawa N., Nonaka I., Sugita H., Maruyama K., Suzuki K. Structure and physiological functions of ubiquitous and tissue-specific calpain species. Muscle-specific calpain, p94, interacts with connectin/titin. Adv. Biophys. 33:1996;101-122.
13. Wang K., Yuen P. Calpain inhibition: an overview of its therapeutic potential. Trends Pharm. Sci. 15:1994;412-419.
14. Banik N., Chakrabarti A., Konat G., Gantt-Wilford G., Hogan E. Calcium-activated neutral proteinase (calpain) activity in C6 cell line compartmentation of mu- and m-calpain. J. Neurosci. Res. 31:1992;708-714.
15. Brustis J., Elamani N., Sofware A. Rat myoblast fusion requires exteriorized m-calpain activity. Eur. J. Cell Biol. 64:1994;320-327.
16. 2+-dependent proteases (calpains) in post mortem proteolysis and meat tenderness. Biochimie. 74:1992;239-245.
17. Audesirk T., Pedersen C., Audesirk G., Kern M. Low levels of inorganic lead noncompetitively inhibit mu-calpain. Toxicology. 131:1998;169-174.
18. Salamino F., De Tullio R., Mengotti P., Melloni E., Pontremoli S. Different regulation of mu- and m-calpain in rat hearts perfused with Ca and cAMP degradation. Biochem. Biophys. Res. Commun. 202:1994;1197-1203.
19. Pontremoli S., Viotti P., Michetti R., Salamino F., Sparatore B., Melloni E. Modulation of inhibitory efficiency of rat skeletal muscle calpastatin by phosphorylation. Biochem. Biophys. Res. Commun. 187:1992;751-759.
20. Kawasaki H., Kawashima S. Regulation of the calpain-calpastatin system by membranes. Mol. Membr. Biol. 13:1996;217-224.
21. Kawasaki H., Emori Y., Suzuki K. Calpastatin has two distinct sites for interaction with calpain-effect of calpastatin fragments on the binding of calpain to membranes. Arch. Biochem. Biophys. 305:1993;467-472.
22. Goll D., Thompson V., Taylor R., Christiansen J. Role of the calpain system in muscle growth. Biochimie. 74:1992;225-233.
23. 2+-dependent proteinases and their inhibitor in normal, fasted, and denervated rat skeletal muscle. Anat. Record. 232:1992;60-77.
24. Nishimura T., Goll D. Binding of calpain fragments to calpastatin. J. Biol. Chem. 266:1991;11842-11850.
25. Nagao S., Saido T., Akita Y., Suzuki K. Calpain-calpastatin interaction in epidermal carcinoma KB cells. J. Biochem. 115:1994;1178-1184.
26. Melloni E., Michetti M., Salamino F., Minafra R., Pontremoli S. Modulation of the calpain autoproteolysis by calpastatin and phospholipids. Biochem. Biophys. Res. Commun. 229:1996;193-197.
27. Baki A., Tompa P., Alexa A., Molnar O., Friedrich P. Autolysis parallels activation of mu-calpain. Biochem. J. 318:1996;897-901.
28. Ouali A. Proteolitic physicochemical mechanisms involved in meat texture development. Biochimie. 74:1992;251-267.
29. Goll D., Thompson V., Taylor R., Zalewska T. Is calpain activity regulated by membranes and autolysis or by calcium and calpastatin? Bioessays. 14:1992;549-556.
30. Tompa P., Baki A., Schad E., Friedrich P. The calpain cascade. Mu-calpain activates m-calpain. J. Biol. Chem. 271:1996;33161-33164.
31. 2+-channel in skeletal muscle. J. Membr. Biol. 142:1994;281-288.
32. Zhang H., Johnson P. Differential effects of aluminum ion on smooth muscle calpain I and calpain II activities. Int. J. Biochem. 24:1992;1773-1778.
33. 3. Biochem. Soc. Trans. 21:1993;444S-448S.
34. Johnson G., Watson A., Lartius R., Uemura E., Jope R. Dietary aluminum selectively decreases MAP-2 in brains of developing and adult rats. Neurotoxicology. 13:1992;463-474.
35. A.A. Boldyrev, Carnosine, Moscow University Press, Moscow, 1998, p. 320.
36. Koohmaraie M. Effect of pH, temperature, and inhibitors on autolysis and catalytic activity of bovine skeletal muscle mu-calpain. J. Anim. Sci. 70:1992;3071-3080.
37. Guttmann R., Elce J., Bell P., Isbell J., Johnson G. Oxidation inhibits substrate proteolysis by calpain I but not autolysis. J. Biol. Chem. 272:1997;2005-2012.
38. Suzuki T., Okumura-Noji K., Ogura A., Zhang RW., Mellgren R. Calpain subunits remain associated during catalysis. Biochem. Biophys. Res. Commun. 227:1996;891-896.
39. Zhang W., Mellgren R. Calpain subunits remain associated during catalysis. Biochem. Biophys. Res. Commun. 227:1996;891-896.
40. Dutt P., Arthur J., Croall D., Elce J. m-Calpain subunits remain associated in the presence of calcium. FEBS Lett. 436:1998;367-371.
41. Zimmerman U.J., Schlaepfer W.W. Two-stage autolysis of the catalytic subunit initiates activation of calpain I. Biochim. Biophys. Acta. 1078:1991;192-198.
42. Johnson G., Guttmann R. Calpains intact and active? Bioessays. 19:1997;1011-1018.
43. Azuma M., Fukiage C., David L., Shearer T. Activation of calpain in lens: a review and proposed mechanism. Exp. Eye Res. 64:1997;529-538.
44. Kuo W., Ganesan U., Walbey D., Davis D., Allen K., McCall L. Modulation of the activity of calpain II by phosphorylation-changes in the proteolysis of cyclic AMP-dependent protein kinase (peak II, DEAE). Appl. Theor. Electrophor. 3:1993;317-320.
45. Kuo W., Ganesan U., Davis D. Regulation of the phosphorylation of calpain 2 and its inhibitors. Mol. Cell. Biochem. 136:1994;157-161.
46. Rosser B., Powers S., Gores G. Calpain activity increases in hepatocytes following addition of ATP. Demonstration by a novel fluorescent approach. J. Biol. Chem. 268:1993;23593-23600.
47. Watt F., Molloy P. Specific cleavage of transcription factors by thiol protease, m-calpain. Nucl. Acids Res. 21:1993;5092-5100.
48. Walowitz J., Bradley M., Chen S., Lee T. Proteolytic regulation of the zinc finger transcription factor YY1, a repressor of muscle-restricted gene expression. J. Biol. Chem. 273:1998;6656-6661.
49. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implication for cellular regulation. Nature. 334:1988;661-665.
50. 4-induced oxidative stress. Biochem. Biophys. Res. Commun. 194:1993;635-641.
51. Oda A., Druker B., Ariyoshi H., Smith M., Salzman E. pp60src is an endogenous substrate for calpain in human blood platelets. J. Biol. Chem. 68:1993;12603-12608.
52. Frangioni J., Oda A., Smith M., Salzman E., Neel B. Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets. EMBO J. 12:1993;4843-4856.
53. Domanska-Janik K., Zablocka B., Zalewska T., Zajac H. Phosphorylation of protein kinase C substrate proteins in rat hippocampal slices - effect of calpain inhibition. Acta Neurobiol. Exp. (Warsz). 58:1998;247-252.
54. 2+ homeostasis contributes to the toxicity of nitric oxide in cultured hippocampal neurons. J. Neurochem. 69:1997;1882-1889.
55. Walker G., Pfeilschifter J., Kunz D. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in interferon (IFN)-gamma-stimulated RAW 264.7 cells by dexamethasone. Evidence for glucocorticoid-induced degradation of iNOS protein by calpain as a key step in post-transcriptional regulation. J. Biol. Chem. 272:1997;16679-16687.
56. Falchetto R., Vorherr T. The calmodulin-binding site of the plasma membrane Ca pump interacts with the transduction domain of the enzyme. Protein Res. 1:1992;1613-1621.
57. Huang J., Forsberg N. Role of calpain in skeletal-muscle protein degradation. Proc. Natl. Acad. Sci. USA. 95:1998;12100-12105.
58. 2+ restoration by calpain. Cell Calcium. 14:1993;455-463.
59. Brandt N., Caswell A., Brandt T., Brew K., Mellgren R. Mapping of the calpain proteolysis products of the junctional foot protein of the skeletal muscle triad junction. J. Membr. Biol. 127:1992;35-47.
60. 2+ release in calpain treated rabbit skinned muscle fibers. Biochem. Biophys. Res. Commun. 185:1992;713-718.
61. Shevchenko S., Feng W., Yarsanyi M., Shoshan-Barmatz V. Identification, characterization and partial purification of a tiol-protease which cleaves specifically the muscle ryanodine receptor/Ca-release channel. J. Membr. Biol. 161:1998;33-43.
62. Doctor R., Bennett V., Mandel L. Degradation of spectrin and ankyrin in the ischemic rat kidney. Am. J. Physiol. 264:1993;C1003-C1013.
63. Yoshida K., Yamasaki Y., Kawashima S. Calpain activity alters in rat myocardial subfractions after ischemia or reperfusion. Biochim. Biophys. Acta. 1182:1993;215-220.
64. Kirchberger M., Borchman D. Phospholamban is regulator of calpains. Biochemistry. 25:1986;5484-5492.
65. 2+-channel. FEBS Lett. 323:1993;229-232.
66. Miyazaki Y., Nomura S., Miyake T., Kagawa H., Kitada C., Taniguchi H., Komiyama Y., Fujimura Y., Ikeda Y., Fukuhara S. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood. 88:1996;3456-3464.
67. Pontremoli S., Melloni E. Extralysosomal protein degradation. Annu. Rev. Biochem. 55:1986;455-481.
68. Zolotarjova N., Ho C., Mellgren R., Askari A., Huang W. Different sensitivities of native and oxidized forms of Na+/K+-ATPase to intracellular proteinases. Biochim. Biophys. Acta. 1192:1994;125-131.
69. Dwyer-Nield L., Miller A., Neighbors B., Dinsdale D., Malkinson A. Cytoskeletal architecture in mouse lung epithelial cells is regulated by protein-kinase C-alpha and calpain II. Am. J. Physiol. 270:1996;L526-L534.
70. 2+/calmodulin-dependent protein kinase II. J. Neurosci. Res. 34:1993;642-647.
71. Greenwood J., Troncoso J., Costello A., Johnson G. Phosphorylation modulates calpain-mediated proteolysis and calmodulin binding of the 200-kDa and 160-kDa neurofilament proteins. J. Neurochem. 61:1993;191-199.
72. Dourdin N., Balcerzak D., Brustis J., Poussard S., Cottin P., Ducastaing A. Potential m-calpain substrates during myoblast fusion. Exp. Cell. Res. 246:1999;433-442.
73. Tashiro T., Ishizaki Y. A calcium-dependent protease selectively degrading 160 000 Mr component of neurofilaments is associated with the cytoskeletal preparation of the spinal cord and has an endogenous inhibitory factor. FEBS Lett. 141:1982;41-44.
74. Billger M., Troncosa J. Calpain processing of brain microtubules from the athlantic cod. Mol. Cell. Biochem. 121:1993;85-92.
75. 2+/calmodulin-dependent protein kinase II: metabolic and functional consequences. J. Neurochem. 59:1992;2056-2062.
76. Litersky J., Johnson G. Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain. J. Biol. Chem. 267:1992;1563-1568.
77. Banik N., Chou A., Derbler T. Peptide bond specifity of calpain. J. Neurosci. Res. 37:1994;489-496.
78. Hong J., Lanzino M., Goto T. Calcium-activated proteolysis in rat neurocortex, induced by ischemia. Brian Res. 661:1994;43-50.
79. Kim K., Homma Y., Ikeuchi Y., Suzuki A. Effect of high hydrostatic pressure on the conversion of alpha-connectin to beta-connectin. J. Biochem. 114:1993;463-467.
80. Elvira M., Diez J., Wang K., Villalobo A. Phosphorylation of connexin-32 by protein kinase C prevents its proteolysis by mu-calpain and m-calpain. J. Biol. Chem. 268:1993;14294-14300.
81. Elvira M., Wang K., Vilalobo A. Phosphorylated and non-phosphorylated connexin-32 molecules. Biochem. Soc. Trans. 22:1994;793-796.
82. Iizuka K., Kawaguchi H., Kitabatake A. Effects of thiol protease inhibitors on fodrin degradation during hypoxia in cultured myocytes. J. Mol. Cell. Cardiol. 25(suppl 9):1993;1101-1109.
83. Lin J., Fitzgerald S., Dong Y., Knight C., Donaldson P., Kistler J. Processing of the gap junction protein connexin50 in the ocular lens is accomplished by calpain. Eur J. Cell Biol. 73:1997;141-149.
84. Yamagich R., Maki M., Sabe H. Unphosphorylated and phosphorylated forms of focal adhesion protein. FEBS Lett. 356:1994;114-116.
85. Elamani N., Balcerzak D., Soriano M., Brustis J., Cottin P., Poussard S., Ducastaing A. Evidence for fibronectin degradation by calpain II. Biochimie. 75:1993;849-853.
86. Sakai K., Fujii T., Hayashi T. Conformational change precedes the formation of multimeric fibronectin. J. Biochem. 119:1996;58-62.
87. Resing K., Blomquist C., Pale B. Independent regulation of two cytoplasmatic processing stages of the intermediate filament-associated protein filaggrin and role of Ca in the second stage. J. Biol. Chem. 268:1993;25139-25145.
88. Patel Y., Lane M. Role of calpain in adipocyte differentiation. Proc. Natl. Acad. Sci. USA. 96:1999;1279-1284.
89. Garach-Jehoshua O., Ravid A., Liberman U., Reichrath J., Glaser T., Koren R. Upregulation of the calcium-dependent protease, calpain, during keratinocyte differentiation. Br. J. Dermatol. 139:1998;950-957.
90. Giasson B., Bruening W., Durham H., Mushynski W. Activation of stress-activated protein kinases correlates with neurite outgrowth induced by protease inhibition in PC12 cells. J. Neurochem. 72:1999;1081-1087.
91. Mellgren R., Lu Q., Zhang W., Lakkis M., Shaw E., Mericle M. Isolation of a Chinese hamster ovary cell clone possessing decreased mu-calpain content and a reduced proliferative growth rate. J. Biol. Chem. 271:1996;15568-15574.
92. Possard S., Gotti P., Brustis J., Talmat S. Quantative measurement of calpains 1 and 2 mRNAs in differentiating rat muscle cells using a comparative polimerase reaction method. Biochimie. 75:1993;885-890.
93. Kumar A., Shafiq S., Wadgaonkar R., Stracher A. The effect of protease inhibitors, leupeptin and E64d, on differentiation of C2C12 myoblasts in tissue culture. Cell. Mol. Biol. 38:1992;687-691.
94. Wu N., Jay Y., Stracer M. Existence of multiple phosphorylated forms of human platelet actin binding protein. Cell. Mol. Biol. Res. 40:1994;351-354.
95. Coelho M., Larson R. Ca2+-dependent phosphorylation of the tail domain of myosin-V, a calmodulin-binding myosin in vertebrate brain. Braz. J. Med. Biol. Res. 26:1993;465-472.
96. Cheng Y. Oxidative mechanisms involved in kainate-induced cytotoxicity in cortical neurons. Neurochem. Res. 19:1994;1557-1564.
97. Sarin A., Adams D., Henkart P. Protease inhibitors selectively block T cell receptor-triggered programmed cell death in a murine T cell hybridoma and activated peripheral T cells. J. Exp. Med. 178:1993;1693-1700.
98. Mampuru L., Chen S., Kalenik J., Bradley M., Lee T. Analysis of events associated with serum deprivation-induced apoptosis in C3H/Sol8 muscle satellite cells. Exper. Cell Res. 226:1996;372-380.
99. Lu Q., Mellgren R. Calpain inhibitors and serine protease inhibitors can produce apoptosis in HL-60 cells. Arch. Biochem. Biophys. 334:1996;175-181.
100. Vanags D., Porn-Ares M., Coppola S., Burgess D., Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J. Biol. Chem. 271:1996;31075-31085.
101. Squier M., Cohen J. Calpain, an upstream regulator of thymocyte apoptosis. J. Immunol. 158:1997;3690-3697.
102. Kubbutat M., Vousden K. Proteolytic cleavage of human p53 by calpain, a potential regulator of protein stability. Mol. Cell. Biol. 17:1997;460-468.
103. Spinedi A., Oliverio S., Di Sano F., Piacentini M. Calpain involvement in calphostin C-induced apoptosis. Biochem. Pharmacol. 56:1998;1489-1492.
104. Knepper-Nicolai B., Savill J., Brown S. Constitutive apoptosis in human neutrophils requires synergy between calpains and the proteasome downstream of caspases. J. Biol. Chem. 273:1998;30530-30536.
105. Villa P., Henzel W., Sensenbrenner M., Henderson C., Pettmann B. Calpain inhibitors, but not caspase inhibitors, prevent actin proteolysis and DNA fragmentation during apoptosis. J. Cell Sci. 111:1998;713-722.
106. 2 to rat kidney proximal tubule epithelial cells. Pathobiology. 62:1994;298-310.
107. Braun C., Engel M., Seifert M., Theisinger B., Seitz G., Zang K., Welter C. Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. Int. J. Cancer. 84:1999;6-9.
108. Kelley M., David L., Iwasaki N., Wright J., Shearer T. Alpha-Crystallin chaperone activity is reduced by calpain II in vitro and in selenite cataract. J. Biol. Chem. 268:1993;18844-18849.
109. Shearer T., Shih M., Mizuno T., David L. Crystallins from rat lens are especially susceptible to calpain-induced light scattering compared to other species. Cur. Eye Res. 15:1996;860-868.
110. Mouatt-Prigent A., Karlsson J., Agid Y., Hirsch E. Increased m-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience. 73:1996;979-987.
111. Kampfl A., Posmantur R., Nixon R., Grynspan F., Zhao X., Liu S., Newcomb J., Clifton G., Hayes R. mu-Calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. J. Neurochem. 67:1996;1575-1583.
112. Meldrum B. Protection against ischaemic damage by drugs acting on excitatory neurotransmission. Cerebrovasc. Brain Metabol. Res. 2:1990;27-57.
113. Pettigrew L., Holtz M., Craddock S., Minger S., Hall N., Geddes J. Microtubular proteolysis in focal cerebral ischemia. J. Cerebr. Blood Flow Metabol. 16:1996;1189-1202.
114. Siman R., Bozyczko-Coyne D., Savage M., Roberts-Lewis J. The calcium-activated protease calpain I and ischemia-induced neurodegeneration. Adv. Neurol. 71:1996;167-175.
115. Zalewska T. Calpain as proposed target for neuroprotective treatment of brain ischemia. Folia Neuropathol. 34:1996;121-127.
116. Urthaler F., Wolkowicz P., Digerness S., Harris K., Walker A. MDL-28170, a membrane-permeant calpain inhibitor, attenuates stunning and PKC epsilon proteolysis in reperfused ferret hearts. Cardiovasc. Res. 35:1997;60-67.
117. Minger S., Geddes J., Holtz M., Craddock S., Whiteheart S., Siman R., Pettigrew L. Glutamate receptor antagonists inhibit calpain-mediated cytoskeletal proteolysis in focal cerebral ischemia. Brain Res. 810:1998;181-188.
118. Ostwald K., Hagberg H., Andine P., Karlsson J. Upregulation of calpain activity in neonatal rat brain after hypoxic-ischemia. Brain Res. 630:1993;289-294.
119. Rami A., Ferger D., Krieglstein J. Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. Neurosci. Res. 27:1997;93-97.
120. Rami A., Krieglstein J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res. 609:1993;67-70.
121. Kuki K., Maeda K., Takauchi S., Kakigi T., Maeda S., Tanaka C. Neurochemical and pathological alterations following infusion of leupeptin, a protease inhibitor, into the rat brain. Dementia. 7:1996;233-238.
122. Tijsen M., Peters S., Bindels R., van Os C., Wetzels J. Glycine protection against hypoxic injury in isolated rat proximal tubules: the role of proteases. Nephrol. Dial Transplant. 12:1997;2549-2556.
123. Nixon R., Saito K., Grynspan F., Griffin W., Katayama S., Honda T., Mohan P., Shea T. Calcium-activated neutral proteinase (calpain) system in ageing and Alzheimer's disease. Ann. NY Acad. Sci. 747:1994;77-91.
124. Soldati L., Alberoni M., Bianchi G., Canal N., Franceschi M. Erythrocytic calpain-calpastatin system in Alzheimer's disease. Aging. 8:1996;106-108.
125. Steiner H., Capell A., Pesold B., Citron M., Kloetzel P., Selkoe D., Romig H., Mendla K., Haass C. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. 273:1998;32322-32331.
126. Tsuji T., Shimohama S., Kimura J., Shimizu K. m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. Neurosci. Lett. 248:1998;109-112.
127. Persson H., Kawashima S., Karlsson J. Immunohistochemical localization of calpains and calpastatin in the rabbit eye. Brain Res. 611:1993;272-278.
128. Banik N. Pathogenesis of myelin breakdown in demyelinating diseases: role of proteolytic enzymes. Crit. Rev. Neurobiol. 6:1992;257-271.
129. Li Z., Hogan E., Banik N. Role of calpain in spinal cord injury increased calpain immunoreactivity in rat spinal cord after impact trauma. Neurochem. Res. 21:1996;441-448.
130. 2+-activated neural proteinase activity (calpain) in neural and non-neural tissue: a comparative study. Neurochem. Res. 17:1992;797-802.
131. Bartus R., Chen E., Lynch G., Kordower J. Cortical ablation induces a spreading calcium-dependent, secondary pathogenesis which can be reduced by inhibiting calpain. Exp. Neurol. 155:1999;315-326.
132. Posmantur R., Kampfl A., Siman R., Liu J., Zhao X., Clifton G., Hayes R. A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. Neuroscience. 77:1997;875-888.
133. Robinson A. Inhibiting calpain, rescuing cells. CMAJ. 154:1996;193-195.
134. Yoshida K., Harada K. Proteolysis of erythrocyte-type and brain-type ankyrins in rat heart after postischemic reperfusion. J. Biochem. 122:1997;279-285.
135. Iizuka K., Kawaguchi H., Yasuda H., Kitabatake A. The role of calcium activated neutral protease on myocardial cell injury in hypoxia. Jpn Heart J. 33:1992;707-715.
136. Toda G. Calpain inhibitor E64c decreased injured zone of ischemia heart. Jpn Heart J. 30:1989;357-386.
137. Guttmann R., Johnson G. Oxidative stress inhibits calpain activity in situ. J. Biol. Chem. 273:1998;13331-13338.
138. Belcastro A., Shewchuk L., Raj D. Exercise-induced muscle injury: a calpain hypothesis. Mol. Cell. Biochem. 179:1998;135-145.
139. Spencer M., Lu B., Tidball J. Calpain II expression is increased by changes in mechanical loading of muscle in vivo. J. Cell Biochem. 64:1997;55-66.
140. Beckmann J., Richard I., Broux O., Fougerousse F., Allamand V., Chiannilkulchai N., Lim L., Duclos F., Bourg N., Brenguier L., Pasturaud P., Quetier F., Roudaut C., Sunada Y., Meyer J., Dincer P., Lefranc G., Merlini L., Topaloglu H., Tome F., Cohen D., Jackson C., Campbell K., Fardeau M. Identification of muscle-specific calpain and beta-sarcoglycan genes in progressive autosomal recessive muscular dystrophies. Neuromusc. Disord. 6:1996;455-462.
141. Inomata M., Nomura K., Takehana M., Saido T., Kawashima S., Shumiya S. Evidence for the involvement of calpain in cataractogenesis in Shumiya cataract rat (SCR). Biochim. Biophys. Acta. 1362:1997;11-23.